Please assess the completion status of the following clinical trial:

Trial Title: Seprafilm Slurry in the Prevention of Uterine Scarring in Patients Undergoing Hysteroscopic Myomectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Reproductive aged women: Age 18-48 years old~* Non-pregnant~* Otherwise healthy~* Regular menstrual cycle~* Documented submucosal myomas (one or more)~* Undergoing hysteroscopic myomectomy~* Patients must have signed an informed consent.~Exclusion Criteria:~* Age \< 18 or in menopause~* Undergoing a second uterine surgical procedure~* Other significant uterine pathology (including but not limited to adhesions, septae, or cancerous lesions)~* Hysteroscopic evidence of synechiae at the time of the procedure~* Surgeries complicated by excessive bleeding; defined by estimated blood loss \> 100cc given that the presence of excessive bleeding may predispose a patient to the formation of intrauterine adhesions~* Surgeries complicated by uterine perforation~* Surgeries complicated by postoperative intrauterine infection given that infection may predispose a patient to the formation of intrauterine adhesions (If these patients received Seprafilm Slurry, they will continue to be followed for safety monitoring)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 48 Years
- Healthy Volunteers: t

Study Arms:
- Seprafilm Slurry (Type: ACTIVE_COMPARATOR): The investigators hypothesize that by placing a slurry of Seprafilm in the intrauterine cavity and creating a temporary physical barrier between the walls of the uterus, that we will be able to prevent iatrogenic intrauterine adhesions. Given that approximately 24 to 48 hours after placement, the membrane becomes a hydrated gel that is slowly resorbed within one week, we anticipate that the patient will have minimal to no discomfort; since no physical device is being left in the endometrial cavity, the uterus will not be contracting more than it does in its normal postoperative state.
- Placebo (Type: PLACEBO_COMPARATOR): For those randomized not to receive Seprafilm slurry, a syringe will be filled with 25ml of sterile saline.

Based on this trial design, predict the completion outcome and termination type (if applicable).